文献速递真菌感染

艾沙康唑用于侵袭性真菌病预防和治疗:一项真实世界观察性研究

Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

这项回顾性观察研究纳入99例接受艾沙康唑治疗的患者,评估其真实世界用法、治疗药物监测数据及疗效安全性。艾沙康唑常超说明书用于非经典宿主因素及非曲霉、非毛霉感染,多因其安全性被选用;77例中29例(37.7%)治疗前7天平均AUC24高于60 mg·h/L,个体暴露普遍偏低且变异大。

要点

  • 艾沙康唑在真实世界中常超说明书用于非经典宿主及非曲霉、非毛霉感染。
  • 因安全性常被选用,包括既往三唑类治疗出现毒性表现者。
  • 77例中29例(37.7%)前7天平均AUC24高于60 mg·h/L,暴露普遍偏低且变异大。

核心结论

  • 艾沙康唑用于多样患者人群且总体耐受良好,个体暴露普遍偏低且变异大。
  • 作者经验显示艾沙康唑是既往唑类治疗后的可行替代选择。

研究设计与样本

  • 回顾性观察性研究,基于回顾性数据评估接受艾沙康唑治疗的患者,共99例。
  • 通过非线性混合效应模型计算治疗前7天平均AUC24,并与现行期望下限目标AUC 60 mg·h/L比较。

主要发现

  • 艾沙康唑常超说明书用于非经典宿主因素及非曲霉、非毛霉感染患者。
  • 艾沙康唑最常因安全性被选用,包括既往三唑类治疗出现毒性表现者。
  • 治疗药物监测及后续剂量调整被频繁进行。
  • 治疗前7天个体平均AUC24高于60 mg·h/L者为77例中29例(37.7%)。

关键数值与推荐

  • 现行期望下限目标AUC为60 mg·h/L。
  • 77例中29例(37.7%)治疗前7天平均AUC24高于60 mg·h/L。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Isavuconazole is a relatively new antifungal agent indicated for the management of various invasive fungal diseases (IFDs), including invasive aspergillosis. Information on real-world experience with isavuconazole is scarce. This retrospective observational study aimed to describe the usage of isavuconazole in clinical practice with an in-depth evaluation of individual isavuconazole exposure. METHODS: Patients treated with isavuconazole were evaluated based on retrospective data, including therapeutic drug monitoring (TDM) data and efficacy and safety data. Additionally, we calculated the individual isavuconazole exposure described by the average AUC24 over the first 7 days of treatment by means of non-linear mixed-effects modelling and compared this with the currently desired lower target AUC of 60 mg·h/L. RESULTS: Ninety-nine patients treated with isavuconazole were evaluated. In our real-life cohort, isavuconazole was often deployed off-label in patients with non-classical host factors and infections with non-Aspergillus and non-Mucorales species. Isavuconazole was most often chosen for its safety profile, even after prior triazole treatment with manifestations of toxicity. TDM and subsequent dosage adjustments were frequently performed. The individual average AUC24 over 7 days was above 60 mg·h/L in 29 out of 77 (37.7%) patients. CONCLUSIONS: This overview provides practical insights that can aid clinicians in the management of their patients with IFD. Our study shows that isavuconazole was used in a diverse patient population and was well tolerated overall. Individual isavuconazole exposure reflected by the average AUC24 over the first 7 days of treatment was generally low and variable. Dosage adjustments following TDM were frequently performed. Our experience shows that isavuconazole is a feasible alternative after prior azole treatment.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ergün M, Jansen AME, Hilbrands LB, et al. Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study. J Antimicrob Chemother. 2024. PMID: 38935893. doi:10.1093/jac/dkae139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。